CEREBROLYSIN®

Dosage and administration

Cerebrolysin has an indication-specific dosing, with the most common regime being intramuscular injections of 5 ml once daily. Studies indicate that Cerebrolysin was also used subcutaneously, though the dosages were 0.5 - 1.0 ml and the effectiveness was lower.

Way of Administration

Please use sterile needles, sterilize the administration site, wear sterile plastic gloves, administer as soon as you opened the vial. Please relax your muscle and inject slowly.

 

Side effects

Cerebrolysin has an excellent safety record. Unless taken in large amounts (>10 ml), the side effects are rare and may include fatigue, headaches, dizziness and insomnia.

Contraindications

Cerebrolysin is not recommended for people who are taking anti-depressants or MAO-inhibitors, or have kidney issues.

Country of Manufacture: Austria

You can read the full instruction here

Please keep at the room temperature - no need to keep in refrigerator.

US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out

It is now hard to believe, but Cerebrolysin ® - perhaps the most efficient peptide nootropic - was developed when the scientific community had a very limited understanding of how the central nervous system works.

The drug was created in 1949 by Gerhart Harrer, an Austrian Professor, and approved on 1 August 1954. After many success stories, extensive research and discovery of neurotrophic regulation, its popularity has increased drastically and now it can officially be used as a treatment for various cerebral disorders in 44 countries, mostly in Europe and Asia.

Cerebrolysin ® is a neurometabolic stimulator based on neuropeptides (20%) and amino acids (80%) isolated from pig brain tissue.

Unlike the majority of peptide drugs, Cerebrolysin has all the amino acids which compose the central nervous system; this can explain many additional positive properties of Cerebrolysin.

Cerebrolysin has been proven to be efficient when used for:
  • Strokes and stroke complications
  • Alzheimer's disease and other types of dementia
  • Traumatic brain injuries
  • Spinal cord injuries
  • ADHD in children
  • Antidepressant-resistant depressions
  • Other cerebral diseases
Like Semax, Cerebrolysin is on the Russian List of Vital & Essential Drugs.

 

Country of Manufacture: Austria

Here you can read more TopBrainBoosters review of Cerebrolysin

Here is the original 84-pages Cerebrolysin Monograph from EverNeuro Pharma, where you can find a lot of information

And here is the Certificate Of Analysis, where you can find the information on one of the batches that we sold. It was asked by one of our clients and we went an extra mile.

One of customer's reviews on Reddit

Legal Disclaimer

This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.

This product is not intended to diagnose, treat, cure, or prevent any disease.

  1. Rutheret al (1994) Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with Senile Dementia of the Alzheimer Type (SDAT) https://www.ncbi.nlm.nih.gov/pubmed/8159781
  2. L. Francis-Turner, V. Valouskova (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study https://www.ncbi.nlm.nih.gov/pubmed/8848264
  3. Schwab et al (1997) Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats - protective effects of Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/9085071
  4. V. Valouskova and A. Gschanes (1999) Effects of NGF, b-FGF, and Cerebrolysin on Water Maze Performance and on Motor Activity of Rats: Short- and Long-Term Study https://www.ncbi.nlm.nih.gov/pubmed/10082636
  5. Masliah et al (1999) Cerebrolysin Ameliorates Performance Deficits, and Neuronal Damage in Apolipoprotein E-Deficient Mice https://www.ncbi.nlm.nih.gov/pubmed/9972690
  6. Bae et al (2000) A Double-Blind, Placebo-Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease https://www.ncbi.nlm.nih.gov/pubmed/11129744
  7. Ruther et al (2000) Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy https://www.ncbi.nlm.nih.gov/pubmed/11005546
  8. Ruether et al (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11552768
  9. Hartbauer et al (2001) Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons https://www.ncbi.nlm.nih.gov/pubmed/11475013
  10. Hartbauer et al (2001) Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons https://www.ncbi.nlm.nih.gov/pubmed/11459078
  11. Eder et al (2001) Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats https://www.ncbi.nlm.nih.gov/pubmed/12197668
  12. Panisset et al (2002) Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent https://www.ncbi.nlm.nih.gov/pubmed/12111446
  13. Rockenstein et al (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance https://www.ncbi.nlm.nih.gov/pubmed/14628195
  14. Ladurner et al (2004) Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial https://www.ncbi.nlm.nih.gov/pubmed/15583955
  15. Alvarez et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/16420392
  16. Rockenstein et al (2006) Cerebrolysin Decreases Amyloid-b Production by Regulating Amyloid Protein Precursor Maturation in a Transgenic Model of Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/16511867
  17. Wei et al (2007) Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/17318304
  18. Ren et al (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats https://www.ncbi.nlm.nih.gov/pubmed/17473393
  19. Alvarez et al (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury https://www.ncbi.nlm.nih.gov/pubmed/18273537
  20. Muresanu et al (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration https://www.ncbi.nlm.nih.gov/pubmed/18048059
  21. Alvarez et al (2009) Reduced TNF-a and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/19531281
  22. Sharma et al (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat https://www.ncbi.nlm.nih.gov/pubmed/20633118
  23. Guekht et al (2011) Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/20656516
  24. Alcantara-Gonzalez et al (2012) Combined Administration of Cerebrolysin and Donepezil Induces Plastic Changes in Prefrontal Cortex in Aged Mice https://www.ncbi.nlm.nih.gov/pubmed/22826038
  25. Heiss (2012) Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial https://www.ncbi.nlm.nih.gov/pubmed/22282884
  26. Menon et al (2012) Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals https://www.ncbi.nlm.nih.gov/pubmed/22229324
  27. Chen et al (2013) Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study https://www.ncbi.nlm.nih.gov/pubmed/23656173
  28. Amiri-Nikpour et al (2014) Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/25516711
  29. Muresanu et al (2015) Cerebrolysin and Recovery After Stroke (CARS) A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/26564102
  30. Ziganshina et al (2016) Cerebrolysin for acute ischaemic stroke https://www.ncbi.nlm.nih.gov/pubmed/27918088


Type: Peptides




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT